Not checkedNot checked for notices yet.
Research Progress of Targeted Therapy for BRAF Mutation in Advanced Non-small Cell Lung Cancer
Xia LIU, Diansheng ZHONG
Chinese Journal of Lung Cancer · 2018
doi:10.3779/j.issn.1009-3419.2018.08.10 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NSCLC) with sensitive driver gene mutations. BRAF is considered a promising oncogenic driver in NSCLC after the discovery of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion and ROS1 rearrangement. BRAF V600E mutation accounts for more than half of BRAF mutations, which is a potential therapeutic target for advanced NSCLC. This review aims to summarize the advancements of BRAF gene mutation and targeted therapy for BRAF mutation in NSCLC.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.